OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel: Oxford, UK Wednesday, November 12, 2025, 17:00 Hrs [IST] Oxford Gene Technology (OGT), a Sysmex ...

Q3 2025 Earnings Call Transcript November 4, 2025 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is ...

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...

Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) ...

Detailed price information for Astellas Pharma Inc (ALPMF) from The Globe and Mail including charting and trades.

Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual Meeting Preliminary data from the ongoing Phase ...

Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients ...

Patients with newly diagnosed acute myeloid leukemia (AML) now have access to oral decitabine/cedazuridine combinations that ...

An Iranian knowledge-based company has successfully developed “Midovens,” a domestically produced anti-cancer drug that ...

Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a ...

Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...